However, GLP-1-based therapies aren't going to be the only option in the weight loss medicines market forever. Some companies are pursuing other approaches that could be even more effective or complementary to the existing interventions.

Men, Baby Boomers, and postgraduate degree-holders were among those most likely to say they wouldn’t choose medication over dieting.

Fewer than 20% of large employers are covering GLP-1 weight loss drugs like Ozempic, a new KFF analysis shows.

WeightWatchers said it will sell compounded versions of semaglutide — the key ingredient in Novo Nordisk's Ozempic and Wegovy.

Research shows patients taking weight-loss drugs like Ozempic and Wegovy are more likely to have food left in the stomach or stool left in the bowel before an endoscopy or colonoscopy.

The embattled diet brand said it is adding a compounded weight-loss drug in accordance with FDA rules and manufacturing standards. WeightWatchers announced on Tuesday that it will offer a compounded version of Novo Nordisk‘s popular weight-loss drug Wegovy as part of its weight-management programs,

Allowing Medicare to cover popular weight loss drugs such as Wegovy and Zepbound could increase federal spending by billions of dollars, according to a new report by the Congressional Budget Office (CBO).